Synthesis and Optimization of Human Serum Albumin Nano particles for Drug Delivery Application
Subject Areas : Information Technology in Engineering Design (ITED) Journal
Keywords:
Abstract :
Abstract In recent years, the application of protein nanoparticles has become of more and more interest to the pharmaceutical industry. In this study,Human Serum Albumin (HSA) was used for the synthesis of nanoparticles by desolvation method for application in drug delivery system because of biodegradablity, owing to the high capacity of drug loading and nontoxiticty. Moreover, the effects of different parameters i.e. pH, HSA concentration, agitation speed, glutaraldehyde concentration, organic solvent adding rate, the ratio of organic solvent/HSA solution were examined in this research and Taguchi method with L16 orthogonal array was implemented to optimize experimental conditions. The best parameters for nanobioparticles production were obtained at pH=9, HSA concentration: 75 mg.ml-1 , ethanol adding rate: 1.5 ml.min-1 and the ratio of organic solvent/HSA solution: 4. Under these conditions, the software predicted the 46.625 nm for HSA nanoparticle size, which, in experiment 53 nm, was achieved for the nanoparticles. With respect to our study, the synthesis of human serum albumin nanoparticles was carried out for the first time and to the best of our knowledge, no reference has been found in the literature about using Taguchi method for optimization of HSA nanoparticles up to now.
[1] RH Miiller; “Colloidal carriers for controlled drug delivery and targeting”. Wissenschaftliche verlagsgesellschaft: Stuttgart, Germany and CRC Press: Boca Raton, 1991. [2]S Cohen, H Bernstein (eds); “Microparticulats systems for the delivery of proteins and vaccines”, Marcel Dekker, New York, 1996. [3] R Gref, Y Minamitake, MT Peracchia, V Trubetskoy, VP Torchilin, R Langer; “Biodegradable long-circulating polymeric nanospheres”, Science 263, 1994, 1600. [4]G Panyam, V Labhasetwar: “Biodegradable nanoparticles for drug and gene delivery to cells and tissue”, Advanced Drug Delivery Reviews, Vol. 55, 2003, 329-347. [5] F Yuan, M Dellian, M Fukumura, M Leunig, BD Berk, VP Torchilin, RK Jain; “Vascular permeability in a human tumor xenograft, Molecular size dependence and cutoff size”, Cancer Res55, 1995, 3752. امل داروهای ضدسرطان سازی نانوذرات پروتئینی آلبومین و ژلاتین به عنوان ح سنتز، جداسازی و خالص 55 [6] M Rahimnejad, M Jahanshahi, G. D Njafpour: “Production of biological nanoparticles from bovine serum albumin for drug delivery”, Afr. J. Biotechnol, 5 (20), 2006, 1918-1923. [7] L Brannon-Peppas, J.O Blanchette; “Nanoparticle and targeted systems for cancer therapy”, Advanced Drug Delivery Reviews, Vol. 56, 2004, 1649-1659. [8] M Jahanshahi, G. D Njafpour, M Rahimnejad; “Applying Taguchi method for optimized fabrication of bovine serum albumin (BSA) nanoparticles as drug delivery vehicles”, Afr. J. Biotechnol, 7(4), 2008, 362. [9] M Jahanshahi, M H Sanati, S Hajizadeh, Z Babaei; “Gelatin nanoparticle fabrication and optimization of the particle size”, Phy. Stat. sol. (a), 2008, 1-5. [10] M Jahanshahi, Z Babaei; “Protein nanoparticle: A unique system as drug delivery Vehicles”, Afr. J. Biotechnol, 7(25), 2008, 4926-4934. [11]Hand book of drug delivery systems, Nanoparticles. [12] Protein Concentration and Diafiltration by Tangential Flow Filtration, [Internet source], Millipore, Viewed 2007-10-01, Available at: http://www.millipore.com/techpublications/tech1/tb032 [13] M Jahanshahi, Z Zhang, ALyddiatt; “Subtractive chromatography for purification and recovery of Nano-bioproducts”, J.IEE Proc-Nanobiotechnol, 152(3), 2005, 121-126. [14] J.J Marty, R.C Oppenheimer, P Speiser; “Nanoparticles-a new colloidal drug delivery system”, Pharm. Acta Helv, 53, 1978, 17-23. [۱۵ [سید عباس شجاع الساداتی، محمد علی اسـدالهی، بیوتکنولوژی صنعتی. انتشـارات دانشـگاه تربیـت مدرس، ۱۳۸۱ . [16] J Kreuter; “Peroral administration of nanoparticles”, Adv Drug Del Rev 7(1), 1991, 71-86. [17] MP Desai, V Labhasetwar, E Walter, RJ Levy, GL Amidon; “The mechanism of uptake of biodegradable microparticles in Caco-2 cells in size dependent”, Pharm Res 14 , 1997, 1568 -1573. [18] M Jahanshahi, MH Sanati , Z Babaei; “Optimization of parameters for the fabrication of gelatin nanoparticles by the Taguchi robust design method”, Journal of Applied Statistics, 35, 12, 2008, 1345–1353,
_||_